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Abstract
Background: Interstitial lung disease (ILD) is a severe systemic manifestation of rheumatoid arthritis (RA). High-
resolution computed tomography (HRCT) represents the gold standard for the diagnosis of ILD, but its routine use for
screening programs is not advisable because of both high cost and X-ray exposure. Velcro crackles at lung auscultation
occur very early in the course of interstitial pneumonia, and their detection is an indication for HRCT. Recently, we
developed an algorithm (VECTOR) to detect the presence of Velcro crackles in pulmonary sounds and showed good
results in a small sample of RA patients.
The aim of the present investigation was to validate the diagnostic accuracy of VECTOR in a larger population of RA
patients, compared with that of the reference standard of HRCT, from a multicentre study.
Methods: To avoid X-ray exposure, we enrolled 137 consecutive RA patients who had recently undergone
HRCT. Lung sounds of all patients were recorded in 4 pulmonary fields bilaterally with a commercial electronic
stethoscope (ES); subsequently, all HRCT images were blindly evaluated by a radiologist, and audio data were
analysed by means of VECTOR.
Results: Fifty-nine of 137 patients showed ILD (43.1%). VECTOR correctly classified 115/137 patients, showing
a diagnostic accuracy of 83.9% and a sensitivity and specificity of 93.2 and 76.9%, respectively.
Conclusions: VECTOR may represent the first validated tool for the screening of RA patients who are suspected
for ILD and who should be directed to HRCT for the diagnosis.
Moreover, early identification of RA-ILD could contribute to the design of prospective studies aimed
at elucidating unclear aspects of the disease.
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Background
Rheumatoid arthritis (RA) is a chronic inflammatory
disease secondary to immune system dysfunction,
characterized by synovial joint swelling and tenderness
with joint destruction and progressive disability. RA is
often complicated by extra-articular manifestations,
and interstitial lung disease (ILD) is one of the most
frequent and deleterious complications with a negative
impact on both the therapeutic approach and overall
prognosis [1–4].
Approximately 10% of the RA population develops
clinically significant ILD that is responsible for not only
decreased quality of life and progressive chronic disabil-
ity but also for 10–20% of deaths associated with the
disease, with a mean survival of 5–8 years [5, 6].
Since no controlled studies are available, the thera-
peutic approach to RA-ILD is still debated and further
complicated by the supposed role of many conventional
and biologic disease-modifying anti-rheumatic drugs
(DMARDs) in the onset or worsening of pre-existing
ILD [7, 8]. In this regard, the British Society of Rheuma-
tology has specifically cautioned prescribing TNFi to pa-
tients with RA-ILD, while in 2008, the American College
of Rheumatology (ACR) contraindicated methotrexate
for the treatment of these patients [9]. In fact, current
literature data are not able to fill the gap of knowledge
in this intriguing matter. Considering the possible sever-
ity of this complication and the therapeutic implications,
investigating a better approach to obtain an early diag-
nosis is mandatory.
High-resolution computed tomography (HRCT)
represents the gold standard for the diagnosis of this
extra-articular manifestation, but ILD can appear in
any stage of RA, entailing the need for a systematic
assessment of lung involvement, and routine use of
HRCT for screening programs is not advisable for both
high cost and X-ray exposure [10].
In this background, a delayed diagnosis could be
responsible for possible severe complications; therefore,
the use of reliable and non-invasive tools may improve
early diagnosis and better management of the disease.
A Velcro sound is a pulmonary sound defined as a fine
crackle that is soft and short in duration, similar to the
sound heard when the joined strips of jogging shoes are
slowly separated. The detection of this typical sound,
generally present throughout the inspiratory time and
persisting after several deep breaths, has been proposed
as an easy and repeatable screening for the early diagno-
sis of idiopathic pulmonary fibrosis and other forms of
ILD [11, 12]. Recently, we developed an algorithm,
named VECTOR (VElcro Crackles detecTOR), to detect
the presence of Velcro crackles in pulmonary sounds
recorded by an electronic stethoscope (ES) and that
showed good results in a low sample of RA patients. In
this preliminary study, the diagnostic accuracy of VEC-
TOR was 90%, with a sensitivity of 92.6% and a specifi-
city of 88.4% [13].
The aim of the present study was to validate the
diagnostic accuracy of VECTOR in a larger population
of RA patients, compared with that of the reference
standard of HRCT, from a multicentre study.
Patients and methods
The InsPIRAtE (INterStitial Pneumonia in Rheumatoid
ArThritis with an Electronic device) study involved
seven Italian tertiary rheumatologic centres with clinical
experience in rheumatic disorders and interstitial lung
diseases after approval from the local ethical committee.
All patients were evaluated by means of VECTOR, and
the results (presence or absence of Velcro crackles) were
compared in a blind manner with HRCT (presence or
absence of ILD).
Inclusion criteria
All consecutive RA patients, classified according to
1987 or 2010 ACR classification criteria [14, 15], with a
recent HRCT evaluation were eligible for the study and
enrolled in a six-month period. According to clinical
history, HRCT should have been performed within 12
months in the absence of the subsequent appearance or
variation of signs or symptoms suggestive of lung dis-
ease (cough, dyspnoea, Velcro sound at routine clinical
examination).
The reason for HRCT prescription was not a selection
criterion for participation in the study.
Exclusion criteria
Exclusion criteria were represented by:
– significant variations in respiratory symptoms after
HRCT imaging (when possible, a new HRCT was
requested);
– presence of pleural effusion or pneumothorax at
HRCT;
– an overlap diagnosis with connective tissue disease.
Study design
According to our previous experience, respiratory
sounds were recorded in 4 pulmonary fields bilaterally
(2 at the basal field, 1 at the middle field and 1 at the
upper field; see Fig. 1) in a silent environment with a
commercial ES (Littmann 3200™ 3M, USA). Then, audio
files acquired for each patient were digitized, coded,
saved as a WAV file and analysed by mean of VECTOR.
Moreover, all HRCT images were transferred on
DICOM format, anonymized, coded and evaluated in a
blind manner by an expert thoracic radiologist for the
assessment of ILD.
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Moreover, for all patients, the value of forced vital
capacity (FVC), diffusion capacity of the lungs for CO
(DLCO), the results of thoracic X-rays, the presence of
Velcro crackles during thoracic examination and the
presence of cough or dyspnoea at baseline were recorded.
Assessment of lung involvement
Radiological All HRCT exams were performed using
different multidetector scanners with a slice thickness of
less than 2mm, from the lung apices to below the costo-
phrenic angles, reconstructed using an edge-enhancing
algorithm. The scan was performed in the supine position
at full inspiration. All images were viewed at a window
setting optimized for assessment of the lung parenchyma
(width 1500 HU; level − 700 HU). HRCT scans were
assessed by an expert chest radiologist who interpreted the
radiologic pattern of ILD according to American Thoracic
Society, European Respiratory Society, Japanese Respira-
tory Society and Latin American Thoracic Association
statement on the diagnosis of idiopathic pulmonary fibro-
sis (IPF) [16, 17]. The pattern of disease was recorded as
definite, possible and inconsistent with usual interstitial
pneumonia (UIP) (see Table 1). If an inconsistent UIP pat-
tern was noted, we specified whether it was compatible
with nonspecific interstitial pneumonia (NSIP), organizing
pneumonia (OP) or lymphoid interstitial pneumonia (LIP)
[18, 19]. When radiologic findings were not suggestive of
any ILD, the radiologist recorded the presence of nodules,
pleural effusion or other isolated manifestations of
pulmonary disease such as consolidation.
Functional The results of pulmonary function tests
were expressed as the percentage of the predicted value
of each parameter and corrected for age, gender and
height. Pulmonary function was considered abnormal if
FVC was < 75% of predicted values. Single breath DLCO
was used to assess gas transfer. A cut-off of 47% was
chosen to identify a severe reduction in DLCO accord-
ing to previous data [20].
Statistical analysis Data were analysed using STATA
statistical software (version 11, StataCorp LP, College
Station, Texas, USA). Categorical variables were
analysed by a chi square test, and differences between
the means were determined using the Mann-Whitney
or Student t-test for unpaired samples. Accordingly, the
diagnostic accuracy, specificity and sensitivity of the
clinical and instrumental diagnostic tools were calcu-
lated. P values ≤0.05 were considered statistically
significant [21].
Fig. 1 All patients were auscultated bilaterally in 4 pulmonary fields
at the dorsal level: 2 at the basal field, 1 at the middle field and 1 at
the upper field
Table 1 Clinical and serological features of 137 patients with rheumatoid arthritis
Total ILD - ILD + p
Nr. 137 78 59
Smoke (%) 37.2 39.7 34 ns
Sex M/F 1/1.83 1/2.54 1/1.31 ns
ACPA (%) 77.2 77.1 77.2 ns
Rheumatoid factor (%) 78.6 81.1 75.4 ns
Forced vital capacity (% ± SD) 91.8 ± 22.3 93.1 ± 21.3 90.3 ± 23.7 ns
DLCO (% ± SD) 59.9 ± 18.0 65.7 ± 20.4 54.4 ± 13.6 0.015
Disease duration (years±SD) 11.1 ± 9.5 10.4 ± 7.8 12.1 ± 11.3 ns
Mean age at disease onset (years±SD) 56.1 ± 12.9 55.3 ± 12.3 57.0 ± 13.6 ns
Mean age at study entry (years±SD) 67.9 ± 9.9 66.5 ± 10.3 69.8 ± 9.1 0.049
ILD Interstitial lung disease, M Males, F Females, ACPA Anti-citrullinated peptide antibodies, DLCO Diffusion lung capacity of CO, SD Standard deviation
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Results
General data
One hundred forty RA patients were enrolled in the study.
Three patients were excluded for a low quality of recorded
lung sounds. The indications for the HRCT were
dyspnoea accompanied or not by fine crackles at lung
auscultation (25.4%), a suggestive thorax X-ray (17.4%),
the presence of fine crackles at lung auscultation (12.3%)
and cough (4.3%). The remaining 56 patients underwent
HRCT for other reasons (i.e., monitoring of lung nodules,
infections, and screening for tumour or other lung
diseases).
The clinical and serological features of the 137
patients investigated are reported in Table 1. ILD was
detected in 59 patients (43.1%). No differences were
observed between patients with or without ILD with
regard to sex, autoantibodies, smoking habit, spirometry
(FVC), mean age at disease onset, and disease duration.
In contrast, patients with ILD were older and showed a
lower DLCO than non-ILD patients (Table 1).
Diagnostic accuracy of VECTOR
VECTOR correctly classified 115/137 patients (83.9%),
showing a sensitivity and specificity of 93.2 and 76.9%,
respectively. Only 4/59 patients with ILD were not iden-
tified by VECTOR, while false positive cases were 18/78.
The diagnostic accuracy of VECTOR for detecting ILD
was higher than that for detecting dyspnoea (64.6%),
cough (58.3%), DLCO (54.9%), FVC (52.8%) and chest
X-ray (71.3%) (see Table 2). The rheumatologist (GC,
not blinded) correctly identified crackles in 69.1% of
patients with ILD (versus 93.2% by using VECTOR) but
also detected crackles in 34.2% of patients without ILD
(versus 23.1% by using VECTOR).
VECTOR correctly identified patients with ILD despite
their radiological pattern (Table 3). The 4 false negative
patients showed an OP in two cases and an UIP pattern
in the other two. The 2 patients with UIP patterns had
advanced and clinically evident lung fibrosis, with diffi-
culty properly breathing deeply. Patients with OP had a
non-typical distribution of lung involvement that could
interfere with proper auscultation. The possible patchy
distribution of OP could explain the missing detection
of these patients. Regarding false positive cases, 12/18
showed an airway disease, mainly bronchiectasis chronic
bronchitis and obliterative bronchiolitis.
The diagnostic accuracy of VECTOR was not influenced
by the duration of lung disease or by the extension of lung
involvement.
Discussion
The present multicentre study confirmed the high sensi-
tivity, specificity and diagnostic accuracy of VECTOR
for detecting the presence of ILD in patients with RA.
RA-ILD is a field of great interest for both rheumatol-
ogists and pulmonologists. In recent years, many studies
have been conducted to elucidate different facets of this
harmful clinical problem, but they are all retrospective,
with substantial bias due to diagnostic methodologies
[22–25].
An early diagnosis of RA-ILD is mandatory since it
represents one of the most severe and challenging extra-
articular manifestations in RA patients, associated with
very low quality of life and poor overall prognosis [1–4].
Given its significant impact, there is a need to develop
strategies to increase the diagnosis of ILD before symp-
tom occurrence. Moreover, ILD can occur at any stage
of the disease; for this reason, a lung evaluation should
always be included in the clinical assessment of RA
patients, regardless of the disease duration or activity.
Currently, screening for RA-ILD is not feasible mainly
because of the low diagnostic accuracy of any method
other than HRCT, resulting in misdiagnosis or delayed
diagnosis [6, 7, 10].
This limitation was already suggested in 2001 by
Dawson et al., who showed the low diagnostic accuracy
of clinical and functional features in RA-ILD patients.
Among cases with HRCT evidence of ILD, only the
presence of bilateral basal chest crackles was signifi-
cantly associated with ILD, while restrictive pulmonary
function tests and bilateral chest radiographic signs of
ILD showed a very low diagnostic accuracy for ILD.
Table 2 Diagnostic accuracy of clinical and instrumental
variables
Total Diagnostic accuracy Specificity Sensitivity
Dyspnoea 29.1 64.6 81.3 41.2
Dry cough 12.1 58.3 89.2 15.1
Thoracic X-ray 35.1 71.3 80 57.8
DLCO < 47% 26 54.9 80 30.8
FVC < 70% 18.9 52.8 82.1 20
Velcro cracklesa 49.2 67.2 65.7 69.1
VECTOR 52.9 83.9 76.9 93.2
apresence of Velcro crackles according to rheumatologist’s auscultation (AM)
Table 3 Diagnostic accuracy according to the HRCT pattern
Nr % Diagnostic accuracy (%)
UIP 30 21.7 93.5
NSIP 11 8 100
OP 8 5.8 75
LIP 1 0.7 100
Other 10 7.2 100
Normal 78 56.5 81.8
HRCT High resolution computerized tomography, UIP Usual interstitial
pneumonia, OP Organizing pneumonia, LIP Lymphocytic interstitial
pneumonia, NSIP Nonspecific interstitial pneumonia
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Additionally, DLCO was associated with ILD, but 52% of
patients had a reduced DLCO without ILD [26]. On the
other hand, to study the possible risk factors for ILD
appearance or progression, the natural evolution of lung
disease and its prognosis, it is crucial to assess the whole
clinical history of ILD and identify patients with subclin-
ical lung involvement.
VECTOR could represent the first validated tool for
the screening of RA patients suspected for ILD and who
should be directed to HRCT for the diagnosis.
Our software, in combination with an ES, showed a
sensitivity and specificity of 93.2 and 76.9%, respectively,
and a very good diagnostic accuracy (83.9%), which is
higher than any other method available to date, except
for HRCT, but without any radiological exposure. The
diagnostic accuracy of VECTOR was also higher than
the capability of an expert rheumatologist to detect
Velcro sounds by means of a pneumatic stethoscope,
which reduced the prescription of needless HRCT and
increased the diagnosis of ILD before clinical manifesta-
tions became evident. Of interest, in our population, less
than half of the patients correctly identified by VECTOR
showed clinical symptoms or a reduction in functional
lung tests, confirming the usefulness of VECTOR in the
identification of subclinical forms of ILD (Table 2).
RA is the most frequent inflammatory rheumatic disease
with a high risk of developing ILD, but to date, a system-
atic approach to this problem is not routinely engaged in
clinical practice [1, 5, 7, 27]. The proposed algorithm
could represent an opportunity for all rheumatologists to
improve the screening of patients to direct HRCT. It can
be combined with an ES and allows real-time detection of
Velcro crackles during a routine clinical examination.
The main limitation of our study is its retrospective de-
sign, which could justify a number of false positive cases,
most likely due to transient conditions. Another possible
explanation is the appearance of ILD subsequently to the
HRCT used for the study. For example, in a patient with
an apparent false positive result, an HRCT repeated after
10months highlighted the presence of an initial ILD that
was not visible in the previous evaluation.
We are aware that our population is not completely
comparable with the general RA population, where we
can suppose a lower rate of ILD but also of comorbidi-
ties that could affect the sensitivity and specificity of
the test. We believe that sensitivity is a greater priority
than specificity in the diagnosis of RA-ILD and that a
possible reduction in specificity in a real-world setting
could be justified by the correct identification of
patients with ILD. However, although VECTOR per-
formed well in the studied population, further studies
should confirm its efficacy as a screening tool in
patients with early lung disease and in the real-world
setting of RA.
Conclusion
VECTOR, associated with an ES, could allow a real-time
screening of patients with ILD at rheumatologists, and it
could be helpful in the design of prospective studies in
which RA-ILD patients are identified with the help of
this non-invasive method and followed during all disease
courses.
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